Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update Mar 9, 2020
Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Multiple Myeloma Dose Escalation Study Feb 19, 2020
Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020 Jan 9, 2020
Cellectar Receives Orphan Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL) Jan 6, 2020
Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study Dec 16, 2019
Cellectar Presents Poster at the American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium Dec 13, 2019
Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented at the 61st Annual American Society of Hematology Conference Dec 9, 2019
Cellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference Dec 2, 2019
